TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8933645
Drug: Erythritol (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythritol (0.3 g/kg on Day 1, 0.6 g/kg on Day 2, 1.0 g/kg on Days 3-7)
Study: 1808616
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg every 4 hr for eight doses)
Study: 1808616
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline tablets after ranitidine pretreatment
Study: 1808616
Drug: Immediate-release tablets
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release tablets
Study: 1808616
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline tablets
Study: 6412583
Drug: Benzylpenicillin preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzylpenicillin preparation containing oil and alum monostearate
Study: 6412583
Drug: Benzylpenicillin preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzylpenicillin preparation without oil and alum monostearate
Study: 6412583
Drug: Benzylpenicillin preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzylpenicillin preparation without adjuvants initiated by benzylpenicillin preparation containing oil and alum monostearate
Study: 31079567
Drug: Intravenous zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zoledronic acid (5 mg in 100 ml) applied on the 5th day after ACDF surgery
Study: 24740528
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of ketamine hydrochloride (0.5 mg/kg)
Study: 20945946
Drug: Edaravone 30
Normalized name: edaravone 30 MG in 100 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone 30 mg twice daily for 10-14 days (long-term group)
Study: 20945946
Drug: Edaravone 30
Normalized name: edaravone 30 MG in 100 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone 30 mg twice daily for 3 days (short-term group)
Study: 18720535
Drug: Herbal formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal formulation (Curcuma longa and Tinospora cordifolia)
Study: 15889523
Drug: TCM drugs
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCM drugs
Study: 10535343
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg mifepristone
Study: 1816187
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion (10 mg/kg/6 h)
Study: 1816187
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (10 mg/kg/6 h)
Study: 6355053
Drug: Acyclovir cream
Normalized name: Acyclovir Cream
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir cream for initial genital herpes
Study: 6355053
Drug: Acyclovir cream
Normalized name: Acyclovir Cream
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir cream for recurrent genital herpes
Study: 24916419
Drug: Test dental
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test dental gel
Study: 24916419
Drug: Control dental
Normalized name: Dental Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control dental gel
Study: 19461584
Drug: Cetilistat 80
Normalized name: Cetilistat
DrugBank: Cetilistat (DB06586)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Cetilistat 80 mg t.i.d.
Study: 19461584
Drug: Cetilistat 40
Normalized name: Cetilistat
DrugBank: Cetilistat (DB06586)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Cetilistat 40 mg t.i.d.
Study: 17425687
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of enoxaparin (30 mg b.i.d. or 40 mg o.d.)
Study: 8245337
Drug: Oral disopyramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral disopyramide (800 mg/day)
Study: 8245337
Drug: No pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pharmacological treatment (control)
Study: 3084442
Drug: 2% mupirocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% mupirocin ointment applied four times a day for five days
Study: 2112167
Drug: 2% mupirocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% mupirocin ointment
Study: 31678185
Drug: Host-associated probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Host-associated probiotic (HAP) Enterococcus faecium strain CGMCC1.2136, 108 CFU g-1
Study: 31678185
Drug: Commercial probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial probiotic (CP) Pediococcus acidilactici, 107 CFU g-1
Study: 27389243
Drug: Warfarin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (100 U/kg)
Study: 24668660
Drug: Warfarin (control)
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin (control)
Study: 23034540
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of exercise training and β-blockade
Study: 20948520
Drug: Large portion
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large portion (820 g of pasta)
Study: 20948520
Drug: Small portion
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small portion (410 g of pasta)
Study: 16023759
Drug: Oral aspirin
Normalized name: aspirin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aspirin therapy (150mg daily for 14 days)
Study: 16023759
Drug: Oral aspirin
Normalized name: aspirin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aspirin therapy
Study: 12827577
Drug: Aspirin ingestion
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin ingestion within 7 days of surgery
Study: 12827577
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin ingestion
Study: 12827577
Drug: Central venous
Normalized name: ACCUGUIDE CENTRAL VENOUS CATHETER KIT C1409AK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central venous or peripheral venous infusion of protamine
Study: 9763056
Drug: Ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 400 mg (2x200 mg) once daily for 5 days
Study: 7874847
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone with resistance exercise for 10 weeks
Study: 28190761
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment arms (FEC-DOC and DOC-C)
Study: 20667273
Drug: Foveal presentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foveal presentation with no concurrent task
Study: 20667273
Drug: Foveal presentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foveal presentation with concurrent task
Study: 15022575
Drug: Xiclav (amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiclav (amoxicillin + clavulanic acid) administered parenterally i.v. (adults at a dose of 3 x 1.2 gr i.v.; children at a dose of 3 x 30 mg/kg) with early oral switch therapy (adults at a dose of 3 x 625 mg per os; children at a dose of 3 x 25‐50 mg/kg)
Study: 15022575
Drug: Parenteral regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral regimen without transition to oral dosage form
Study: 8676798
Drug: Pyridoxine (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine (70 mg/day)
Study: 22328739
Drug: BMS945429 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS945429 (80 mg)
Study: 22328739
Drug: BMS945429 (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS945429 (160 mg)
Study: 22328739
Drug: BMS945429 (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS945429 (320 mg)
Study: 21049175
Drug: Steroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid therapy (duration: 1 to 7 years)
Study: 17034006
Drug: Quetiapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (mean dose 119.2 +/- 56.4 mg)
Study: 16274152
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (implants restored after a healing period)
Study: 11898006
Drug: Rush immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rush immunotherapy (RIT) with IFA whole body extract (WBE)
Study: 11898006
Drug: Rush immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rush immunotherapy (RIT) with IFA WBE
Study: 7583862
Drug: Theo-24 (anhydrous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theo-24 (anhydrous extended-release capsules) plus inhaled beta 2-agonist
Study: 7583862
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus inhaled beta 2-agonist
Study: 347106
Drug: Levamisole as
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole as an immune adjuvant in addition to standard therapy
Study: 31734121
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g × 2 whey-enriched protein supplementation
Study: 31083000
Drug: Propofol total
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol total intravenous anaesthesia combined with desflurane anaesthesia
Study: 25427288
Drug: Incisional Local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incisional Local Anesthetic Administration (port infiltration) with ropivacaine 0.5%
Study: 12739685
Drug: Periodontal ligament
Normalized name: human ligament preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal ligament injection (PDLi) with a computerized device (Wand)
Study: 12739685
Drug: Conventional buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional buccal infiltration
Study: 11142541
Drug: Social Effectiveness
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social Effectiveness Therapy for Children (SET-C)
Study: 4061524
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (600 mg of calcium L-aspartate daily)
Study: 30529244
Drug: COPE (Concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPE (Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure)
Study: 29878826
Drug: Team treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Team treatment milieu
Study: 24839984
Drug: Silica gel
Normalized name: Silica gel
DrugBank: Silicon dioxide (DB11132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Silica gel fibre (SGF) in addition to standard treatment
Study: 24839984
Drug: Standard-of-care treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care treatment (S-o-C) alone
Study: 17285423
Drug: MgSO(4) 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgSO(4) 40 mg.kg(‐1)
Study: 15642806
Drug: Vision therapy/orthoptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vision therapy/orthoptics
Study: 15642806
Drug: Placebo vision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vision therapy/orthoptics
Study: 12119223
Drug: GM-CSF (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF (3 mcg/kg intravenous daily for 5 days)
Study: 10466241
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (letrozole, anastrazole)
Study: 10466241
Drug: LH-RH agonists
Normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LH-RH agonists
Study: 10466241
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy regimens (CMF or CAF)
Study: 7473906
Drug: Fluconazole 100
Normalized name: fluconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 100 mg via enteral route
Study: 7473906
Drug: Fluconazole 100
Normalized name: fluconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 100 mg via intravenous (IV) route
Study: 2258807
Drug: Topical nonsteroidal
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nonsteroidal anti-inflammatory agent (0.03% flurbiprofen)
Study: 2258807
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid (1% prednisolone acetate)
Study: 7029684
Drug: Razoxane (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Razoxane (125 mg twice daily for 5 consecutive days every week indefinitely)
Study: 27140802
Drug: Separate-tablet regimen
Normalized name: aspirin Oral Tablet [Anacin Aspirin Regimen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate-tablet regimen (EVG 150mg + COBI 150mg + FTC/TDF 200mg/300mg)
Study: 27140802
Drug: Single-tablet regimen
Normalized name: aspirin Oral Tablet [Anacin Aspirin Regimen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-tablet regimen (EVG/COBI/FTC/TDF)
Study: 23632659
Drug: BZA/CE treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BZA/CE treatment
Study: 19475630
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg oral mecamylamine
Study: 19475630
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg oral mecamylamine
Study: 19475630
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg oral mecamylamine
Study: 19025429
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg/day with prasugrel (60 mg loading dose followed by 10 mg/day)
Study: 19025429
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg/day with clopidogrel (300 mg loading dose followed by 75 mg/day)
Study: 19025429
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg/day with prasugrel or clopidogrel
Study: 10432470
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose methylphenidate (0.28 mg/kg)
Study: 10432470
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose methylphenidate (0.56 mg/kg)
Study: 10432470
Drug: Baseline (off
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline (off drug)
Study: 8853523
Drug: New anti-cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: New anti-cancer agents in phase II studies
Study: 8853523
Drug: New anti-cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: New anti-cancer agents in phase III studies
Study: 8853523
Drug: New anti-cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: New anti-cancer agents in phase IV studies
Study: 6990475
Drug: 14-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-valent pneumococcal capsular polysaccharide vaccine (Pn)
Study: 6990475
Drug: Haemophilus influenzae
Normalized name: HAEMOPHILUS INFLUENZAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemophilus influenzae type b capsular polysaccharide vaccine (Hib)
Study: 27355577
Drug: Repetitive transorbital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive transorbital alternating current stimulation (rtACS) for 50 min daily for 10 days
Study: 27355577
Drug: Sham-stimulation for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-stimulation for 50 min daily for 10 days
Study: 20395940
Drug: L-NMMA infusion
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA infusion after ischemia at wrist level for 1 minute
Study: 20395940
Drug: L-NMMA infusion
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA infusion after ischemia at wrist level for 2 minutes
Study: 20395940
Drug: L-NMMA infusion
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA infusion after ischemia at wrist level for 5 minutes
Study: 20395940
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion after ischemia at upper arm
Study: 10408999
Drug: Awareness group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Awareness group (received specific informational brochures on diet and cardiovascular risk factors and the reasons for the treatment)
Study: 1932649
Drug: Bovine lung
Normalized name: defibrotide, bovine lung
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine lung heparin (BLH)
Study: 1932649
Drug: Porcine mucosal
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine mucosal heparin (PMH)
Study: 7333749
Drug: High blood
Normalized name: Cough & Cold High Blood Pressure Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High blood glucose (G)
Study: 18972125
Drug: Skin protection
Normalized name: NeutrapHor 1% Skin Protection Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin protection and skin care in combination
Study: 17060516
Drug: 2.0-g extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0-g extended-release azithromycin microspheres (single-dose regimen)
Study: 17060516
Drug: 500-mg immediate-release
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500-mg immediate-release azithromycin tablet (3-day regimen)
Study: 23593417
Drug: rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone 4 mg twice daily
Study: 11684346
Drug: Patients not
Normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients not taking aspirin
Study: 11684346
Drug: Patients taking
Normalized name: Lamictal Blue (For Patients Taking Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients taking aspirin
Study: 2907898
Drug: Protocol I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol I: 7 injections of 1,500 IU hCG every other day
Study: 2907898
Drug: Protocol II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol II: 4 injections of 100 IU/kg hCG at 4- to 5-day intervals
Study: 24748286
Drug: Intra-articular PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular PRP injections (3 injections at monthly intervals)
Study: 24748286
Drug: Intra-articular PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular PRP injections (2 cycles of 3 injections)
Study: 16490513
Drug: Ibopamine 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine 2% solution administered as eyedrops
Study: 17974698
Drug: Cell infusion
Normalized name: irrigation set MISCELL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell infusion
Study: 11735095
Drug: Association with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association with concurrent diseases
Study: 3311687
Drug: Cimetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (800 mg) and Pirenzepine (50 mg) at bed-time
Study: 3311687
Drug: Cimetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (800 mg) and Placebo at bed-time
Study: 27385430
Drug: Medication organisation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication organisation devices (MODs) supplied either weekly or monthly
Study: 27385430
Drug: Medication organisation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication organisation devices (MODs)
Study: 27385430
Drug: MOD monthly
Normalized name: MOD-423 hGH analogue
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: MOD monthly
Study: 23532993
Drug: Behaviorally focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviorally focused maintenance treatment (MT)
Study: 23532993
Drug: Socially focused
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Socially focused maintenance treatment (MT)
Study: 11168739
Drug: Subantimicrobial dose
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subantimicrobial dose doxycycline (SDD) 20 mg 2x daily for 12 weeks
Study: 11168739
Drug: Subantimicrobial dose
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subantimicrobial dose doxycycline (SDD) 20 mg 1x daily in part III
Study: 26230671
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day intranasal glutathione
Study: 26230671
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day intranasal glutathione
Study: 24124993
Drug: Modified constraint-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified constraint-induced movement therapy (CIMT at home)
Study: 24124993
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical and occupational therapy (therapy as usual)
Study: 17157113
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir morning injection
Study: 17157113
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir evening injection
Study: 17157113
Drug: NPH evening
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NPH evening injection
Study: 10891736
Drug: Lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60 mg with 2 g of amoxicillin and 1 g of clarithromycin for 10 days
Study: 10891736
Drug: Lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60 mg with 2 g of amoxicillin and 1 g of clarithromycin for 7 days